



Q CHIP LTD PRESS RELEASE 13 SEPTEMBER 2010

Q Chip Ltd raises £2 million in first close funding round

Cardiff, Wales, 13 September 2010 – Q Chip Ltd, a biopharmaceutical company developing innovative sustained release injectable depot formulations, announced today it has reached the first close £2 million of a planned £3 million funding round.

The funds will be invested in scaling-up its Q-Sphera™ technology to meet current Good Manufacturing Practice (cGMP) standards for the production and manufacture of its sustained release peptide and protein therapeutics. This will allow the company to increase levels of production to support the preclinical development of Q-Leuprolide and Q-Octreotide depots as well as partnered projects.

The financing was led by both new and existing shareholders (Curzon Park Capital and Finance Wales). Q-Chip has completed a number of successful financing rounds, securing investment totalling £7.5 million (approx USD11.5 million) to date.

Ken Powell, Q Chip's Executive Chairman, said "The successful closure of this financing round in these challenging economic times demonstrates investor confidence in Q Chip's technology and the compelling advantages it offers to the biopharmaceutical industry. With this funding in hand, Q Chip is now able to establish manufacturing capability, a major milestone for our programmes. It will also allow the development of a sustainable pipeline of partnered programmes."

British venture capitalist and Q Chip investor Jon Moulton said "It is great to see Q Chip reach this point. The up scaling of the Q-Sphera™ production platform is of key strategic importance in the future development of Q Chip's pipeline."

New investor and successful British entrepreneur Sir Harry Solomon said "Q Chip's Q-Sphera technology shows great potential in being a new and 'disruptive' drug delivery technology. This technology will generate great interest in the generics and pharmaceutical industry."

-ends-

NOTES TO EDITORS

Q Chip - www.q-chip.com

Q Chip Ltd is a biopharmaceutical company developing sustained release injectable depot formulations. Q Chip's proprietary encapsulation technology platform, Q-Sphera™, represents a paradigm shift in bioencapsulation technology for the production of drug loaded microspheres.

Q Chip has developed a suite of manufacturing devices which enable the benign processing of polymer/drug formulations into mono-dispersed microspheres for subcutaneous, intra-muscular/ocular administration. These devices are compatible with a wide range of therapies including small molecules, peptides, oligonucleotides, proteins and cells. In addition, microsphere formulation can also be customised to provide sustained release over weeks or months.

Q Chip Investors

Finance Wales - www.financewales.co.uk

Finance Wales is an independent investment company formed in 2001 by the Welsh Assembly Government. Finance Wales commercially invests private and public funds, including EU funds in Wales-based businesses with the potential to grow



Q CHIP LTD PRESS RELEASE 13 SEPTEMBER 2010

Curzon Park Capital - www.curzonparkcapital.com

Curzon Park Capital was set up to provide Private Equity and Venture Capital funding to support the growth of businesses across the Cleantech sector in Europe. Curzon Park Capital has been actively investing in this sector since 2007 through its first Venture Fund - The Sustainable Technology Fund. Their combined team has over 70 years of investment experience and has access to GBP 200 million of equity commitments.

CONTACTS

Corporate

Q Chip Ltd

Chief Strategic Officer Dr Jo Macpherson

Telephone: + 44 (0) 29 2048 0180

Jo.Macpherson@q-chip.com

www.q-chip.com

Media

Capital MSL

Mary Clark, Justine Lamond and Hollie vile

Telephone: +44 (0)20 7307 5337

Justine.lamond@capitalmsl.com